BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 50,000 shares, a growth of 111.0% from the February 28th total of 23,700 shares. Based on an average daily trading volume, of 51,400 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.4% of the shares of the company are sold short.

BioCardia Price Performance

Shares of BCDA opened at $2.68 on Friday. The firm has a market capitalization of $12.29 million, a PE ratio of -0.64 and a beta of 1.28. The company has a 50-day simple moving average of $2.45 and a two-hundred day simple moving average of $2.41. BioCardia has a one year low of $1.63 and a one year high of $6.30.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.62. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. During the same period in the previous year, the firm earned ($8.19) earnings per share. Analysts expect that BioCardia will post -3.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Alliance Global Partners upgraded shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of BioCardia in a report on Wednesday, December 18th.

Insider Buying and Selling

In other news, Director Simon H. Stertzer acquired 22,753 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were acquired at an average price of $2.30 per share, for a total transaction of $52,331.90. Following the completion of the purchase, the director now owns 40,602 shares in the company, valued at approximately $93,384.60. This trade represents a 127.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 25,353 shares of company stock valued at $58,525. 20.00% of the stock is owned by insiders.

Institutional Investors Weigh In On BioCardia

An institutional investor recently raised its position in BioCardia stock. Geode Capital Management LLC boosted its holdings in BioCardia, Inc. (NASDAQ:BCDA) by 110.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,987 shares of the company’s stock after purchasing an additional 16,251 shares during the quarter. Geode Capital Management LLC owned approximately 0.68% of BioCardia worth $68,000 as of its most recent SEC filing. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.